GSK
GSK/Prosensa confirm orphan drug setback
September 23, 2013Sales and Marketing GSK, MD, Prosensa, drisapersen
An experimental treatment by GSK and Prosensa for a rare type of muscle-degenerating disease has failed to meet its primary …
EFPIA slams EMA data proposals
September 10, 2013Research and Development, Sales and Marketing AZ, EFPIA, EMA, GSK, Pfizer, Roche
The intense debate over how pharma should make trial data available has taken another turn as a major European industry …
GSK completes £1.35 billion Suntory deal
September 10, 2013Sales and Marketing GSK, Suntory, lucozade, ribena
GlaxoSmithKline has confirmed it is to sell Lucozade and Ribena to Japanese drinks giant Suntory Beverage & Food for £1.35 …
GSK has ‘serious concerns’ about China
September 9, 2013Medical Communications, Sales and Marketing China, GSK, bribery
GlaxoSmithKline is said to be thinking about abandoning China altogether as the company continues to co-operate with the country’s authorities …
Manufacturing and production news in brief
September 6, 2013Manufacturing and Production GSK, Jabones Pardo, Mylan, Shasun, Wockhardt
A round-up of pharma manufacturing facility news, with updates from Wockhardt, Mylan, GSK and Shasun, plus an FDA warning letter …
GSK may sell Lucozade and Ribena to Japan’s Suntory
September 6, 2013Sales and Marketing GSK, Suntory, lucozde, ribena
GSK is reportedly to sell its Lucozade and Ribena brands to Osaka-based Suntory in a deal worth up to £1.5 …
China may be trying to ‘frighten’ pharma
September 6, 2013Medical Communications, Sales and Marketing China, GSK, Sanofi, bribery
Western pharma companies caught up in Chinese probes over corruption are being discriminated against, according to a European business lobby …
GSK cancer vaccine fails in Phase III
September 5, 2013Research and Development, Sales and Marketing BMS, GSK, Yervoy, melanoma, phase III
GlaxoSmithKline’s hopes of creating a cancer vaccine against the deadliest form of skin cancer took a blow today when its …
GSK faces new China allegations
September 4, 2013Medical Communications, Sales and Marketing China, GSK, bribery
GlaxoSmithKline is facing a potential worsening of its already embarrassing situation in China, where the UK-based group has been accused …
GSK’s skin cancer pill Tafinlar gets EMA approval
September 3, 2013Sales and Marketing BMS, GSK, Tafinlar, Yervoy, melanoma
GSK has been granted EMA marketing authorisation for its new metastatic melanoma drug Tafinlar. The EMA’s decision on Tafinlar (dabrafenib) …
GSK Crohn’s disease pill fails in Phase III
August 27, 2013Sales and Marketing GSK, vercirnon
A late-stage trial of GlaxoSmithKline’s investigational Crohn’s disease drug failed to benefit patients. The SHIELD-1 study was investigating vercirnon – …
Lilly drawn into China bribery scandal
August 22, 2013Medical Communications, Sales and Marketing China, GSK, Sanofi, bribery, corruption, lilly, payments
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
